PHAR

Pharming Group
PHAR
Market cap $751M

10.96 USD

-0.15

1.35%

At close Aug 1, 4:00 PM EDT

1 day

-1.35%

5 days

6.20%

1 month

2.33%

3 months

25.26%

6 months

33.66%

Year to date

4.78%

1 year

43.64%

5 years

-34.37%

10 years

-34.37%

About: Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Employees: 404

Healthcare Biotechnology

0

Funds holding %

of 7,327 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% less ownership

Funds ownership: 0.01% [Q4 2024] → 0.01% (-0%) [Q1 2025]

17% less capital invested

Capital invested by funds: $514K [Q4 2024] → $427K (-$87.6K) [Q1 2025]

40% less funds holding

Funds holding: 5 [Q4 2024] → 3 (-2) [Q1 2025]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PHAR.

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about PHAR published over the past 30 days

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Pharming Group N.V. (NASDAQ:PHAR ) Q2 2025 Earnings Conference Call July 31, 2025 7:30 AM ET Executives Anurag Relan – Chief Medical Officer Fabrice Chouraqui – CEO & Executive Director Stephen Toor – Chief Commercial Officer & GM Americas Analysts Benjamin Jackson - Jefferies Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Simon Scholes - First Berlin Equity Research GmbH Sushila Hernandez - Kempen & Co Fabrice Chouraqui Good morning or good afternoon, everyone, and welcome to our Q2 2025 earnings call.

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Zacks Investment Research

New Strong Buy Stocks for August 1st

ROKU, PHAR, ASC, META and ARI have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2025.

New Strong Buy Stocks for August 1st

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Leiden, the Netherlands, July 31, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025.

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Zacks Investment Research

Best Momentum Stocks to Buy for July 25th

RVLV, PHAR and AMZN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 25, 2025.

Best Momentum Stocks to Buy for July 25th

Zacks Investment Research

New Strong Buy Stocks for July 25th

PHIN, MBWM, THC, RVLV and PHAR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2025.

New Strong Buy Stocks for July 25th

Zacks Investment Research

Best Momentum Stocks to Buy for July 17th

PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.

Best Momentum Stocks to Buy for July 17th

Zacks Investment Research

New Strong Buy Stocks for July 17th

PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.

New Strong Buy Stocks for July 17th

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Leiden, the Netherlands, July 17, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2025 and provide a business update on Thursday, July 31, 2025.

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a definitive APDS diagnosis for many patients Findings reveal APDS may be more prevalent than previously estimated Webcast to take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT Leiden, the Netherlands, June 24, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will host a webcast for investors and analysts featuring Joshua Milner, MD, an internationally renowned immunologist, to discuss the findings of a recent study published in the peer-reviewed journal Cell.

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

See News Rankings

Charts implemented using Lightweight Charts™